Monday, February 24, 2020 Location: Bank of America Tower, 51st Floor, New York Presentation time: 12:50-1:30 p.m. ET Company Attendee: CEO Richard Chin Webcast URL: Click here For more information about this event, please see the press release.
San Francisco, California (February 18, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch Animal Health Summit on February 24 in New York City. Dr. Richard Chin, Chief Executive Officer, will present and be available for one-on-one […]
Positive results from canine pharmacokinetic study demonstrate up to three-fold increase in antibody half-life. Longer half-lives have the potential to reduce dosing frequency, lower doses, and/or reduce cost of goods sold. Technology expected to lead to multiple best-in-class products. San Francisco, California (January 8, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company […]
San Francisco, California (December 16, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results from its randomized, placebo-controlled laboratory pilot study of KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 receptor (IL-4R), for the treatment of atopic dermatitis in dogs. […]
Mirataz is the first and only medication approved in the European Union to treat cats experiencing poor appetite and weight loss resulting from chronic medical conditions. San Francisco, California (December 12, 2019) – Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the […]
San Francisco, California (November 25, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has approved Zimeta™ (dipyrone injection) for the control of pyrexia in horses. Pyrexia, or fever, is associated with […]
Tuesday, November 19, 2019 Location: Lotte New York Palace Hotel Presentation time: 10:20-10:50a.m. ET in Kennedy Company Attendee: CEO Richard Chin Webcast URL: Click here For more information about this event, please see the press release.
Thursday, November 21, 2019 Location: Waldorf Hilton, London Company Attendee: CEO Richard Chin For more information about this event, please see the press release.
San Francisco, California (November 14, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21. Dr. Richard Chin, Chief Executive Officer, will present and be available […]
San Francisco, California (November 12, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2019 and provided updates on its programs. For the third quarter 2019, KindredBio reported net product revenues of $1.1 million and a net loss […]
0.04 (0.39%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
